纳米粒在急性缺血性卒中患者神经保护治疗中的应用  

Application of nanoparticles in neuroprotective therapy for patients with acute ischemic stroke

作　　者：茆康成 孙勇[1] 李爱民 Mao Kangcheng;Sun Yong;Li Aimin(Lianyungang Clinical School of Nanjing Medical University(The First People's Hospital of Lianyungang),Lianyungang 222023,China)

机构地区：[1]南京医科大学连云港临床医学院(连云港市第一人民医院)神经外科,连云港222023

出　　处：《国际脑血管病杂志》2024年第2期127-132,共6页International Journal of Cerebrovascular Diseases

基　　金：江苏省卫健委科研基金项目(ZDA2020018);连云港市老龄健康科研项目(L202301)。

摘　　要：缺血性卒中是全球第二大死亡原因,也是我国人口的主要致死和致残因素。纳米载药系统(nanodrug delivery system,NDDS)通过利用纳米粒子(nanoparticles,NPs)和仿生纳米粒子(biomimetic nanoparticles,BNPs)进行药物输送,能够增加药物输送量和改善生物利用度,从而提高靶向效果,减少不良反应,并提高药物的治疗效果。文章基于缺血性卒中的病理生理学特征,综述了NPs辅助神经保护药在缺血性卒中治疗方面的研究进展,期望为急性缺血性卒中寻找更安全和更有效的治疗手段。Ischemic stroke is the second leading cause of death globally and a major cause of death and disability in China.The nanodrug delivery system(NDDS)utilizes nanoparticles(NPs)and biomimetic nanoparticles(BNPs)for drug delivery,which can increase drug delivery volume and improve bioavailability,thereby improving targeting efficacy,reducing adverse reactions,and enhancing therapeutic outcome.Based on the pathophysiological characteristics of ischemic stroke,this article reviews the research progress of NPs-assisted neuroprotective drugs in the treatment of ischemic stroke,aiming to find safer and more effective treatment methods for acute ischemic stroke.

关 键 词：缺血性卒中 纳米粒 神经保护药 

分 类 号：R743.31[医药卫生—神经病学与精神病学]